Note: The approximately 9-year statement is from a pooled analysis of all explored doses that the safety page cites as a 2025 conference poster (Gordon et al.); the Prescribing Information reports controlled safety data through Week 52.
Do patients develop antibodies to Skyrizi (immunogenicity)?
Applies to Adults with moderate-to-severe plaque psoriasis
Note: The statements on TB evaluation and lab monitoring are from the safety page of the Skyrizi HCP site; the skyrizi-tuberculosis question covers TB evaluation. The liver test schedule in the Prescribing Information applies to Crohn’s disease and ulcerative colitis.